What are the side effects of nivolumab?
Your cancer treatments may be delayed or permanently discontinued if you have certain side effects. Common nivolumab side effects may include: nausea, vomiting, stomach pain, loss of appetite, diarrhea, constipation; cold symptoms such as runny or stuffy nose, cough, sore throat; weight loss.
What is the drug nivolumab used to treat?
Nivolumab will be given to you in combination with ipilimumab for the treatment of malignant pleural mesothelioma. If you have any questions about ipilimumab, please ask your doctor.
Do nivolumab-treated patients develop neurotoxicity more often?
The fact that a higher number of nivolumab-treated patients developed neurotoxicity is consistent with findings of Cuzzubbo and colleagues who reported a higher incidence of nAEs during anti-PD1 therapy.
When is nivolumab used to treat esophageal cancer?
Nivolumab is used: In patients whose esophageal cancer or gastroesophageal junction adenocarcinoma has been treated with a combination of chemotherapy and radiation therapy and then surgery to completely remove the cancer, but cancer cells were found in the removed tumor or lymph nodes.
What type of cancer is nivolumab used for?
Gastric (stomach) cancer, gastroesophageal junction adenocarcinoma, or esophageal cancer that has spread. Nivolumab is used with a fluoropyrimidine and platinum chemotherapy.¹. Hepatocellular carcinoma (a type of liver cancer ). Nivolumab is used alone or with ipilimumab in patients who have already been treated with sorafenib .¹.
What is nivolumab used for?
Nivolumab is used in patients whose cancer got worse during or after treatment with platinum chemotherapy. Urothelial carcinoma (a type of bladder cancer) that has spread. Nivolumab is used in patients whose cancer got worse during or after treatment with platinum chemotherapy.¹. ¹This use is approved under FDA’s Accelerated Approval Program.
Is nivolumab a confirmatory trial?
As a condition of approval, a confirmatory trial (s) must show that nivolumab provides a clinical benefit in these patients. Nivolumab is also being studied in the treatment of other types of cancer.
Can nivolumab be used alone?
Use in Cancer. Nivolumab is approved to be used alone or with other drugs to treat: At least three other types of treatment including an autologous stem cell transplant.¹. Colorectal cancer in adults and children 12 years and older.
Can ipilimumab be used for melanoma?
Nivolumab is sometimes used with ipilimumab. In patients who have had surgery to remove melanoma that has spread to the lymph nodes or has metastasized. Non-small cell lung cancer.
Can you take nivolumab after platinum?
In patients whose cancer is metastatic and has gotten worse during or after treatment with platinum chemotherapy. Patients whose cancer has a mutation in the EGFR or ALK gene should receive nivolumab only if their disease got worse after treatment with FDA -approved therapy for these gene mutations.
What are the side effects of Nivolumab?
Check with your doctor or nurse immediately if any of the following side effects occur while taking nivolumab: More common. Back pain. blistering, peeling, or loosening of the skin. chest tightness. chills.
Does nivolumab need medical attention?
Side effects not requiring immediate medical attention. Some side effects of nivolumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine.
What is nivolumab used for?
Nivolumab, an IgG4 monoclonal antibody for programmed cell death protein 1 (PD-1), exerts its anti-tumor effect by promoting T-cell activation, thereby enhancing the immune reaction against cancer. In recurrent or distant metastatic head and neck cancer, the use of nivolumab as an immune checkpoint inhibitor (ICI) has spread rapidly since its efficacy was demonstrated [ 1 ]. Nivolumab is associated with the onset of autoimmune reactions; therefore, caution is required against immune-related adverse events (irAEs) that occur in systemic organs. Of these events, the incidence of endocrine disorders is reported to be 3.8–29% [ 2, 3 ]. Most of these are thyroid disorders including hypothyroidism, which is the most common thyroid disorder, followed by hyperthyroidism which is the next most common. The incidence of pituitary disorders, especially nivolumab-induced pituitary disorders, is low [ 2, 3 ].
Is nivolumab a symptom of endocrine disorders?
This case of a hypopituitarism due to nivolumab was discovered by a symptom of malaise. Although malaise is experienced by all patients with cancer, it is not always perceived as an important symptom of endocrine disorders. When using ICIs, it is always important to suspect the onset of pituitary disorders and promptly test hormone levels. Prompt initiation of therapy, including replacement therapy, is also linked with the proper diagnosis of irAE-related endocrine disorders. This is beneficial to the patient even from the aspect of the antitumor effects with continued ICI treatment.
0.1 Introduction
The aim of the Early Access to Medicines Scheme (EAMS) is to provide earlier availability of promising new unlicensed medicines (medicines that do not have a marketing authorisation or are used outside their licence) to UK patients that have a high unmet clinical need.
0.3 1. What nivolumab is and what it is used for
Nivolumab is a medicine used to treat malignant pleural mesothelioma (a type of cancer that affects the lining of the lung) in adults.
0.6 4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them. Your doctor will discuss these with you and will explain the risks and benefits of your treatment.
0.8 6. Contents of the pack and other information
The active substance is nivolumab. Each mL of concentrate for solution for infusion contains 10 mg of nivolumab. Each vial contains 100 mg (in 10 mL) of nivolumab.
0.9 Additional information
Informed Consent Form This document will be explained to the patient thoroughly before their treatment commences. The patient will be requested to sign the form and a copy will be given to them to keep.
0.10 Contact information
Bristol-Myers Squibb Medical Information on 0800 731 1736 or [email protected]